Skip to content

Continuous Glucose Monitoring, Diabetes Education, and Peer Support for Management of Uncontrolled Type 2 Diabetes

The COMPASS Program: Continuous Monitoring, Peer And Structured Support for Management of Uncontrolled Type 2 Diabetes - A Prospective Single-Arm Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07054125
Acronym
COMPASS
Enrollment
100
Registered
2025-07-08
Start date
2025-08-01
Completion date
2028-08-31
Last updated
2025-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus - Poor Control

Brief summary

This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes. People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit).

Interventions

BEHAVIORALEducation, lifestyle counseling, and peer support

This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes. People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit).

Sponsors

DexCom, Inc.
CollaboratorINDUSTRY
Whole Endo
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years and older * Diagnosed with type 2 diabetes mellitus Hemoglobin A1c \>8% Must have smartphone to connect with continuous glucose monitor

Exclusion criteria

* Pregnancy Use of steroids Active cancer treatment Terminal illness Dementia, mental impairment Type 1 diabetes End stage renal disease, on dialysis

Design outcomes

Primary

MeasureTime frame
Hemoglobin A1c12 weeks

Countries

United States

Contacts

Primary ContactRashim Gupta, MD
rashim.gupta@wholeendo.com980-349-6036
Backup ContactJavier Samayoa, EdD
javier.samayoa@wholeendo.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026